Neural Regen Res. 2023 Mar;18(3):643-651.doi: 10.4103/1673-5374.350211. (IF6.058) TMEM16F may be a new therapeutic target for Alzheimer’s disease
Cell Mol Immunol . 2022 Sep 1. doi: 10.1038/s41423-022-00917-7. Online ahead of print. USP3 deubiquitinates and stabilizes the adapter protein ASC to regulate inflammasome activation. (IF:22.096).
Antioxidants (Basel). 2022 Aug 19;11(8):1602.doi: 10.3390/antiox11081602. (IF7.675) D-Penicillamine Reveals the Amelioration of Seizure-Induced Neuronal Injury via Inhibiting Aqp11-Dependent Ferroptosis
Genome Res. 2022 Aug 12.doi: 10.1101/gr.275962.121. Online ahead of print. (IF9.438) ceRNA crosstalk mediated by ncRNAs is a novel regulatory mechanism in fish sex determination and differentiation
Antioxidants (Basel). 2022 Aug 19;11(8):1602.doi:10.3390/antiox11081602. D-Penicillamine Reveals the Amelioration of Seizure-Induced Neuronal Injury via Inhibiting Aqp11-Dependent Ferroptosis
Cell Mol Biol Lett. 2022 Jul 30;27(1):64.doi: 10.1186/s11658-022-00360-6. (IF8.702) Granulin as an important immune molecule involved in lamprey tissue repair and regeneration by promoting cell proliferation and migration
Biomed Eng Online. 2022 Jun 17;21(1):39.doi: 10.1186/s12938-022-01002-w. (IF3.903) Restoration of Cullin3 gene expression enhances the improved effects of sonic hedgehog signaling activation for hypertension and attenuates the dysfunction of vascular smooth muscle cells
Environ Pollut . 2022 Sep 1;308:119607. doi: 10.1016/j.envpol.2022.119607. Epub 2022 Jun 16. Methyltransferase-like 3 leads to lung injury by up-regulation of interleukin 24 through N6-methyladenosine-dependent mRNA stability and translation efficiency in mice exposed to fine particulate matter 2.5. (IF:9.988).
Int J Mol Sci. 2022 May 31;23(11):6159.doi: 10.3390/ijms23116159. (IF5.924) Gallic Acid Alleviates Visceral Pain and Depression via Inhibition of P2X7 Receptor
Acta Pharmacol Sin. 2022 Apr 6. doi: 10.1038/s41401-022-00893-8. Online ahead of print. Promoter methylation-regulated miR-148a-3p inhibits lung adenocarcinoma (LUAD) progression by targeting MAP3K9 (IF:6.150).
